<PAGE>
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarter Ended Commission File Number: 1-10432
June 30, 1997
ROBERTS PHARMACEUTICAL CORPORATION
(Exact name of registrant as specified in its charter)
NEW JERSEY 22-2429994
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
MERIDIAN CENTER II
4 INDUSTRIAL WAY WEST
EATONTOWN, NEW JERSEY 07724
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(908) 389-1182
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
--- ---
Class Outstanding Shares at
July 22, 1997
Common Stock 27, 908,663
<PAGE>
ROBERTS PHARMACEUTICAL CORPORATION
INDEX
Page
Part I
Item 1 - Financial Statements 2
Item 2 - Management's Discussion and Analysis 8
Part II
Item 1 - Legal Proceedings 12
Item 6 - Exhibits and Reports on Form 8-K 13
Signatures
<PAGE>
ROBERTS PHARMACEUTICAL CORPORATION
CONSOLIDATED BALANCE SHEETS
(In Thousands)
(Unaudited)
June 30, 1997 December 31, 1996
------------- -----------------
ASSETS:
Current assets:
Cash and cash equivalents $ 82,086 $ 87,125
Marketable securities 9,329 7,793
Accounts receivable, net 30,463 30,791
Inventory 17,895 16,665
Notes receivable, current 206 1,620
Deferred tax assets 9,040 9,040
Net assets held for sale 500 500
Other current assets 3,868 2,124
-------- --------
Total current assets 153,387 155,658
Fixed assets, net 14,996 14,945
Intangible assets 179,678 183,756
Notes receivable 6,703 6,574
Deferred non-current tax asset 11,217 11,217
Other assets 70 74
-------- --------
Total assets $366,051 $372,224
======== ========
The accompanying notes are an integral part of these financial statements.
- 2 -
<PAGE>
ROBERTS PHARMACEUTICAL CORPORATION
CONSOLIDATED BALANCE SHEETS
(In Thousands)
(Unaudited)
June 30, 1997 December 31, 1996
------------- -----------------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current installments of
long-term debt $ 4,547 $ 6,376
Accounts payable 14,300 15,848
Income taxes payable 8,674 7,020
Dividends payable 252 679
Other current liabilities 17,436 21,559
-------- --------
Total current liabilities 45,209 51,482
Long-term debt, excluding
current installments 7,077 10,639
Other liabilities 294 345
Shareholders' equity:
Class B preferred stock,
$.10 par 10,000,000 shares
authorized, 808,822 and
2,721,030 outstanding 81 272
Common stock, $.01 par,
100,000,000 shares authorized,
27,883,309 and 22,961,707
outstanding 284 223
Additional paid-in capital 367,119 365,160
Cumulative translation adjustments (474) (301)
Retained earnings (deficit) (53,302) (55,359)
Treasury stock, 387,594 shares
of common stock, at cost (237) (237)
-------- --------
Total shareholders' equity 313,471 309,758
-------- --------
Total liabilities and
shareholders' equity $366,051 $372,224
======== ========
The accompanying notes are an integral part of these financial statements.
- 3 -
<PAGE>
ROBERTS PHARMACEUTICAL CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT PER SHARE DATA)
(UNAUDITED)
<TABLE>
<CAPTION>
For the six months For the three months
ended June 30, ended June 30,
1997 1996 1997 1996
--------- --------- ---------- ----------
<S> <C> <C> <C> <C>
Sales and Revenue:
Sales $56,616 $44,007 $30,286 $26,791
Other revenue 0 24 0 12
------- ------- ------- -------
Total sales and revenue 56,616 44,031 30,286 26,803
------- ------- ------- -------
Operating costs and expenses:
Cost of sales 24,633 22,393 12,981 13,466
Research & development 2,657 1,996 1,823 847
Marketing & administration 27,062 27,636 14,641 14,966
------- ------- ------- -------
Total operating costs & expenses 54,352 52,025 29,445 29,279
------- ------- ------- -------
Operating income (loss) 2,264 (7,994) 841 (2,476)
------- ------- ------- -------
Other income (expense):
Interest income 2,709 806 1,541 368
Interest expense (432) (1,171) (178) (520)
Foreign currency gain (loss) (64) (13) (51) 127
Other income(expense), net (48) (1) (48) (26)
------- ------- ------- -------
Total other income (expense) 2,165 (379) 1,264 (51)
------- ------- ------- -------
Income (loss) from continuing
operations before income taxes 4,429 (8,373) 2,105 (2,527)
Provision (benefit) for income taxes 1,571 (2,407) 817 (773)
------- ------- ------- -------
Income (loss) from operations 2,858 (5,966) 1,288 (1,754)
Estimated income on disposal of
discontinued division, net of
tax benefit of $2,045 - 3,969 - 3,969
------- ------- ------- -------
Net income (loss) $ 2,858 $(1,997) $ 1,288 $ 2,215
======= ======= ======= =======
Per share of common stock,
primary and fully diluted:
Income (loss) from
continuing operations $ 0.08 $ (0.32) $ 0.04 $ (0.09)
Income from discontinued operations - 0.21 - 0.21
------- ------- ------- -------
Net income (loss) $ 0.08 $ (0.11) $ 0.04 $ 0.12
======== ======== ======== ========
Weighted average number of
common shares outstanding,
primary and fully diluted: 28,885,89 218,695,868 28,616,319 18,658,601
</TABLE>
The accompanying notes are an integral part of these financial statements.
- 4 -
<PAGE>
ROBERTS PHARMACEUTICAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)
For the six months
ended June 30,
1997 1996
------------- ---------------
Cash flows provided by operating activities: $ 3,479 $11,781
------- -------
Cash flows from investing activities:
(Purchase) redemption of marketable securities (1,536) 7,527
Purchases of intangible assets (1,990) (40)
Purchases of fixed assets (382) (78)
Collection of notes receivable 610 0
Impact of discontinued operations 0 2
------- -------
Net cash provided by (used in)
investing activities (3,298) 7,411
------- -------
Cash flows from financing activities:
Payments on notes payable and
long term debt (5,795) (8,280)
Net proceeds from issuance of
common stock 828 (217)
Net proceeds from issuance of
5% Preferred stock 1,000 0
5% Preferred stock dividends paid (1,229) 0
Impact of discontinued operations 0 355
------- -------
Net cash used in
financing activities (5,196) (8,142)
------- -------
Exchange rate changes on cash and
cash equivalents (24) (8)
------- -------
Change in cash and cash equivalents (5,039) 11,042
Beginning cash and cash equivalents 87,125 16,357
------- -------
Ending cash and cash equivalents $82,086 $27,399
======= =======
Supplemental cash flow information:
Interest paid $ 934 $ 438
Income taxes paid $ 8 $ 62
The accompanying notes are an integral part of these financial statements.
- 5 -
<PAGE>
1. Summary of Significant Accounting Policies
------------------------------------------
Basis of Presentation
- ---------------------
In the opinion of management, the accompanying consolidated financial statements
include all necessary adjustments, consisting of normal adjustments, necessary
for a fair presentation of results for the period reported. All dollar amounts
are presented in thousands, except per share data.
Foreign Currency Translation
- ----------------------------
Effective January 1, 1997, the functional currency of the United Kingdom
subsidiary, Monmouth Pharmaceutical, Ltd., was changed from the U.S. Dollar to
the British Pound as a result of change in circumstance. Monmouths' translation
gains and losses will now be accumulated as a separate component of
Shareholders' Equity.
New Accounting Pronouncements
- -----------------------------
In February 1997, the FASB issued SFAS No. 128, "Earnings Per Share." SFAS 128
specifies a new standard designed to improve the earnings per share ("EPS")
information provided in financial statements by simplifying the existing
computational guidelines, revising the disclosure requirements, and increasing
the comparability of EPS data on an international basis. Some of the changes
made to simplify the EPS computations include: (a) eliminating the presentation
of primary EPS and replacing it with basic EPS, with the principal difference
being that common stock equivalents are not considered in computing basic EPS,
(b) eliminating the modified treasury stock method and the three percent
materiality provision, and (c) revising the contingent share provisions and the
supplemental EPS data requirements. SFAS 128 also makes a number of changes to
existing disclosure requirements. SFAS 128 is effective for financial
statements issued for periods ending after December 15, 1997, including interim
periods. The Company has not yet determined the impact of the implementation of
SFAS 128 and therefore this calculation has not been reflected in these
financial statements.
2. Inventory
---------
Inventory at June 30, 1997 consists of:
Raw Materials $ 2,936
Finished Goods 14,959
-------
Total $17,895
=======
-6-
<PAGE>
3. Change in Accounting Estimate
-----------------------------
In second quarter 1997, management made several changes in accounting estimates.
The aggregate amount of these changes is $1.3 million.
4. Contingency
-----------
A shareholder class action suit was instituted March 24, 1995, in the United
States District Court for the District of New Jersey against Roberts
Pharmaceutical Corporation and certain of its officers and a former officer for
alleged violations of certain federal securities laws. The Company is not able
to predict the outcome of this proceeding at this time, and management is not
able to determine the amount of the potential liability, if any. Roberts
Pharmaceutical believes that it has complied with all of its obligations under
the federal securities laws. Roberts Pharmaceutical is defending vigorously
against the plaintiff's allegations and considers such allegations to be without
merit.
5. Subsequent Event
----------------
The Company completed the purchase of a pharmaceutical manufacturing and
packaging facility from Searle Canada, a unit of Monsanto Company, on July 7,
1997.
- 7 -
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Conditions and
Results of Operations
Results of Operations
Six months ended June 30, 1997 and 1996
Corporate Revenues
- ------------------
Total revenue for the six months and quarter ended June 30, 1997 increased $12.6
million and $3.5 million respectively as compared with the first six months of
1996. This increase was due to an increase in revenues from product sales.
Product Sales
- -------------
For the six months ended June 30, 1997, product sales increased $12.6 million
from $44.0 million to $56.6 million primarily as a result of the launch of
AGRYLIN and an increase in sales by the United Kingdom subsidiary.
U.S. product sales increased $8.4 million from $33.0 million to $41.4 million.
AGRYLIN and PROAMATINE provided $5.1 and $1.8 million, respectively, of this
increase, and COLACE, SALUTENSIN, and PERI-COLACE also posted significant
increases of $1.5 million, $0.8 million, and $0.8 million, respectively. These
increases were offset by a decrease in NOROXIN sales of $0.6 million and by the
divestiture of the non-core product lines which occurred in third quarter 1996.
Sales of the Company's United Kingdom subsidiary, Monmouth Pharmaceuticals,
Ltd., increased $3.7 million from $5.2 million to $8.9 million. $2.7 million of
this increase is due to sales of LODINE which was launched in fourth quarter
1996 and $0.5 million is due to an increase in the sales of EMINASE. Sales of
the Company's Canadian subsidiary increased slightly by $0.5 million from $5.8
million to $6.3 million.
Product sales in the second quarter increased $3.5 million from $26.8 million in
1996 to $30.3 million in 1997. Second quarter product sales in the U.S.
increased $2.0 million from $21.5 million in 1996 to $23.5 million in 1997.
Sales in the U.K. increased $1.2 million to $3.6 million in second quarter 1997
from $2.4 million in 1996. Canada's second quarter sales increased to $3.1
million in 1997, a $0.3 million increase from 1996 second quarter sales of $2.8
million.
Cost of Sales
- -------------
For the six months ended June 30, 1997, cost of sales amounted to 43.5% of
product sales, a 7.4 percentage point decrease as compared to the prior year's
comparable period. This decrease in cost of sales and corresponding increase in
gross profit percentage is primarily the result of the addition of AGRYLIN to
the product mix. AGRYLIN has a higher gross profit percentage as it is a
product the development of which was completed internally. Included in cost of
sales is a $1.8 million charge for minimum royalties due to Ortho Pharmaceutical
Corporation for SUPPRELIN sales. Included in these changes is the impact of a
change in accounting estimate.
- 8 -
<PAGE>
Research and Development
- ------------------------
Research and Development expenses increased $0.7 million to $2.7 million and
$1.0 million to $1.8 million during the six and three month periods,
respectively, ended June 30, 1997 as compared to the comparable prior year
periods. This increase is due to $0.5 million for new programs related to the
compounds purchased in 1996 and a $0.4 million increase in registration and user
fees.
Marketing and Administrative Expenses
- -------------------------------------
For the six months ended June 30, 1997, Marketing and Administrative expenses
decreased $0.6 million from $27.6 million to $27.0 million. Marketing expenses
decreased $0.8 million. Contributing factors were a decrease in salaries and
benefits of $0.4 million, a decrease in advertising of $0.7 million, and a
decrease in consulting costs of $1.3 million, offset by increases in samples of
$0.5 million, market research and coupons of $0.7 million, and AGRYLIN launch
expenses of $0.3 million.
Administrative expense increased $0.2 million from $10.9 million to $11.1
million. This increase was due to a number of factors including an increase of
$0.4 million related to salaries and benefits, and a $0.2 million increase
related to outside services offset by a decrease of $0.4 million in legal and
accounting expenses.
For the quarter ended June 30, 1997, Marketing expenses remained constant at
$9.0 million. Administrative expenses decreased $0.3 million from the second
quarter 1996 to $5.6 million in second quarter 1997. Included in the quarter and
year to date changes are the impact of changes in accounting estimate.
Interest Income and Expense
- ---------------------------
Interest income for the six months ended June 30, 1997, increased $1.9 million
as a result of an increase in invested marketable securities arising from the
common and preferred stock offerings in the third quarter of 1996. Interest
expense for the same period decreased by $0.7 million as a result of a decrease
in long-term debt related to product acquisitions.
Income Taxes
- ------------
For the six months ended June 30, 1997 and 1996, income tax expense was
calculated using a normal statutory rate for continuing operations, except for
certain taxes related to foreign operations.
The Company has recorded net deferred tax assets of approximately $20.3 million.
Realization is dependent upon generating sufficient taxable income to utilize
such items. Although realization is not assured, management believes it is more
likely than not that all of the deferred tax assets will be realized; however,
these assets could be reduced at any time if estimates of future taxable income
are reduced.
- 9 -
<PAGE>
Liquidity and Capital Resources
- -------------------------------
Operating activities provided $3.5 million in cash. The primary components of
cash provided by operating activities were a $0.3 million increase in accounts
receivable, net income of $2.9 million, which includes $3.6 million of
non-cash charges, and increased working capital requirements of $2.7 million.
Investing activities used $3.3 million, comprised primarily of $1.5 million in
marketable securities purchases and $1.4 million in collections of notes
receivable offset by asset purchases of $2.0 million.
Financing activities used $5.2 million, including $5.8 million of payments on
notes payable and payment of $1.2 million of preferred stock dividends paid
offset by proceeds from the issuance of Common and Preferred Stock of $1.8
million.
The Company will use its existing cash and securities balances and cash
generated from operations to fund its operating activities and its near-term and
long-term debt obligations from previous product acquisitions. These balances
will also be used to fund future acquisitions of new products and the
development of existing pipeline products as well as the July 1997 purchase of
the manufacturing plant and capital improvements scheduled for that facility.
Foreign Currency Fluctuations
- -----------------------------
Roberts has subsidiary operations outside the United States. As a result,
Roberts is subject to fluctuations in revenues and costs reported in United
States dollars as a consequence of changing currency exchange rates, especially
rates for the British pound and Canadian dollar. Such fluctuations were not
material for the second quarter 1997.
Other
- -----
The Company has been pursuing a number of initiatives over the past year which
have contributed to the increase in earnings. Some of these initiatives have
already resulted in increased sales and decreased expenses, while others are
still in the early phases. Several of these key initiatives are outlined below.
PROAMATINE is undergoing Phase IV FDA clinical trials to eliminate certain
labeling restrictions on the drug. These trials are aimed at establishing the
clear clinical benefits of PROAMATINE, which, if demonstrated, should result in
increased sales. Additional trials of ProAmatine for other indications,
including urinary stress incontinence, are planned.
Roberts expects AGRYLIN to receive approval for sale in Canada in the third or
fourth quarter of 1997 and European approval is expected in mid-1998. The
European market is expected to exceed that of the North American market for this
drug.
- 10 -
<PAGE>
Several changes have been made in the sales force and overall marketing plan to
improve its efficiency. Sales territories have been realigned and the sales
force has been automated, both with the aim of covering high prescribing
physicians with fewer salespeople. This realignment resulted in lower sales
force expenses, as evidenced by the fact that marketing expenses decreased in
the six months ended June 30, 1997 over the six months ended June 30, 1996
despite the expenses incurred for the two new drug launches.
The Company also changed the strategic direction of EMINASE. Formerly, Roberts
maintained a separate sales force for certain products including EMINASE. That
sales force has been merged into the regular sales force and all sales reps have
received Eminase sales training. This change is expected to increase the number
of sales calls and decrease the effect of turnover within the sales force.
In another strategic change, recognizing that managed health care has become a
dominant force in the marketplace, the Company has taken steps to penetrate this
portion of the market and is pursuing managed care contracts and is working to
increase the number of formularies on which its drugs are listed.
The Company intends to use television advertising as part of its promotional
efforts for its COLACE line of products. Such efforts seem to have been
successful previously as sales of COLACE for the six months ended June 30, 1997
increased by $2.3 million over the comparable 1996 period.
The purchase of the manufacturing and packaging facility, completed in early
July 1997, is expected to improve the Company's profitability as production
costs should decrease by producing in house. It is also projected that the
recurring problems of stock-outs and overstocks will be minimized by controlling
the production cycle. OTC sales may also be improved by controlling the
production cycle due to the opportunity to process special packaging runs, such
as bonus packs of COLACE and PERI-COLACE. It has not been feasible to produce
such special packaging utilizing outside production companies.
- 11 -
<PAGE>
Item 1. Legal Proceedings
The Company previously reported in its Current Reports on Form 8K dated April
10, 1995 and June 26, 1995, respectively, and its Quarterly Report on Form 10-Q
for the quarter ended June 30, 1995, that two shareholder class action suits had
been instituted against it and certain of its officers in the United States
District Court for the District of New Jersey. The second suit filed by Dieter
Zander has been voluntarily dismissed by the plaintiff. The first complaint, as
amended, was filed by Grace Cowit on behalf of all persons who purchased shares
of the Company's Common Stock between November 7, 1994 and May 31, 1995.
- 12 -
<PAGE>
Item 6 Exhibits and Reports on Form 8K
Reports on Form 8K
Date of Report
April 21, 1997 Roberts Pharmaceutical Corporation reported first quarter
1997 results with significant year-to-year improvements
recorded in revenues, gross profits, and net earnings.
May 22, 1997 Roberts Pharmaceutical Corporation announced today that Mr.
Joseph N. Noonburg and the Honorable Marilyn Lloyd have
joined its Board of Directors.
Mr. Noonburg, a self-employed consultant, has a 38 year
background in the pharmaceutical industry including serving
as Senior Vice President of Sales for the pharmaceutical
firm of Reed & Carnick. Mr. Noonburg has also been actively
involved in several pharmaceutical industry associations.
Ms. Lloyd, a former Congresswoman from Tennessee's Third
Congressional District, is a consultant for Lockheed Martin
Corporation and the Spectrum Group, and serves on a number
of boards including Secretary Pena's Energy Advisory Board.
During her tenure as Congresswoman she championed many
initiatives promoting health care awareness for women and
chaired the Housing and Consumer Committee of the Committee
on Aging.
Mr. Noonburg and Ms. Lloyd now fill the two seats on the
Board of Directors previously held by Yamanouchi Group
Holding, Roberts largest shareholder. Under the term of a
stock purchase agreement, Yamanouchi is now entitled to
designate only one member of the board for election.
Yamanouchi has noted it continued interest in Roberts future
and, while not designating a nominee to Roberts Board at
this time, retains the right to do so at a future date.
May 22, 1997 Roberts Pharmaceutical Corporation announced that effective
May 22, 1997, the Company's common stock will begin trading
on the American Stock Exchange (AMEX). Roberts common stock
will trade on the AMEX under the symbol RPC.
The Company commented that the move from the dealer oriented
OTC market to the public auction market of AMEX is expected
to provide a trading environment for their common stock
which will be beneficial to their shareholders. Among the
benefits expected
- 13 -
<PAGE>
from a public auction market are a narrowing in the spread
between bid and ask prices; reduced volatility; enhanced
liquidity; and greater visibility.
July 9, 1997 Roberts Pharmaceutical announced that it has completed the
purchase of a pharmaceutical manufacturing facility from
Searle Canada, a unit of Monsanto Company. In addition to
existing manufacturing and packaging operation, the 100,852
square foot facility includes warehouse, administrative, and
QC/QA laboratory space. The facility, located in Oakville
Ontario, is approved by both the U.S. Food and Drug
Administration and the Health Protection Branch of Canada.
Roberts has historically outsourced all its manufacturing
and packaging functions. Plans have been initiated to
effect transfer of production of certain over-the-counter
products from third party manufacturers to Oakville in the
second half of 1997. This will be followed by a phase-in of
the Company's Canadian, U.K and U.S. prescription products.
Also, Searle has agreed to lease back space from Roberts for
a time and has agreed in principle for Roberts to fulfill
certain of Searle's packaging and clinical supply
requirements.
July 9, 1997 Roberts Pharmaceutical Corporation announced today that it
has submitted a Manufacturing Authorization Application
(MAA) for European approval of its new drug Agrylin (TM).
The application has been filed with the European Medicines
Evaluation Agency (EMEA) in accordance with the centralized
procedure for approval of new drugs within the 15-country
European Union (EU).
The EU regulatory authorities have accepted Agrylin (TM) as
a "List B" product, a category given to products considered
to represent new drug treatments or important therapeutic
advances. Under European centralized procedure, a
successful MAA grants product approval through the EU, a
market potential for Agrylin (TM) that could significantly
exceeds that of North America.
- 14 -
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amendment to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: 7/25/97 /s/ Peter M. Rogalin
------------------- ----------------------------
Peter M. Rogalin
Vice President and Treasurer
Date: 7/25/97 /s/ Peter M. Rogalin
------------------- ----------------------------
Peter M. Rogalin
Chief Accounting Officer
- 15 -
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 1997 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> JUN-30-1997
<CASH> 82,086
<SECURITIES> 9,329
<RECEIVABLES> 30,463
<ALLOWANCES> 0
<INVENTORY> 17,895<F1>
<CURRENT-ASSETS> 153,387
<PP&E> 14,996
<DEPRECIATION> 0
<TOTAL-ASSETS> 366,051
<CURRENT-LIABILITIES> 45,209
<BONDS> 7,077
0
81
<COMMON> 284
<OTHER-SE> 313,106
<TOTAL-LIABILITY-AND-EQUITY> 366,051
<SALES> 56,616
<TOTAL-REVENUES> 56,616
<CGS> 24,633
<TOTAL-COSTS> 24,633
<OTHER-EXPENSES> 2,657
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 432
<INCOME-PRETAX> 4,429
<INCOME-TAX> 1,571
<INCOME-CONTINUING> 2,858
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 2,858
<EPS-PRIMARY> .08
<EPS-DILUTED> .08
<FN>
<F1>Includes Raw Material Inventory of $2,936.
</FN>
</TABLE>
